Asenapine is a new atypical antipsychotic which is only licensed in the UK for treating moderate to severe manic episodes with Bipolar I episodes.
It will be officially launched in early 2012, but Ashtons can supply this already. It is not currently licensed in the UK for the treatment of acute schizophrenia or relapse prevention, although it is licensed in the US for this indication.
The efficacy of asenapine is mediated through a combination of antagonist activity at D2 and 5-HT2A receptors. Actions at other receptors e.g. 5-HT1A, 5-HT1B, 5-HT2C, 5-HT6, 5-HT7, D3, and α2-adrenergic receptors, may also contribute to the clinical effects of asenapine.
The recommended dose is 5mg to 10mg twice a day, and it is available as a fast dissolving tablet for sublingual administration.
Further details are available from Lundbeck – email@example.com
Photo taken from here. No changes made.